

NEONATOLOGY TODAY

News and Information for BC/BE Neonatologists and Perinatologists

Volume 6 / Issue 2

February 2011

IN THIS ISSUE

Hypoglycemia and Hyperglycemia in Neonates

by Kaninghat Prasanth, MD, MRCPCH;
Sachin Gupta, MD and Tsu F. Yeh, MD,
PhD

Page 1

'CAN' Syndrome (Cord-Around-the-Neck Syndrome)

by Morarji Peesay, MD; Nitin Mehta,
MBBS

Page 11

DEPARTMENT

April Meeting Focus - Workshop on Perinatal Practice Strategies

Page 9

Global Neonatology Today: A Monthly Column

by Dharmapuri Vidyasagar, MD, FAAP,
FCCM

Page 13

NEONATOLOGY TODAY

Editorial and Subscription Offices

16 Cove Rd, Ste. 200

Westerly, RI 02891 USA

www.NeonatologyToday.net

Neonatology Today (NT) is a monthly newsletter for BC/BE neonatologists and perinatologists that provides timely news and information regarding the care of newborns and the diagnosis and treatment of premature and/or sick infants.

© 2011 by Neonatology Today ISSN: 1932-7129 (print); 1932-7137 (online). Published monthly. All rights reserved.

Statements or opinions expressed in Neonatology Today reflect the views of the authors and sponsors, and are not necessarily the views of Neonatology Today.

Upcoming Meetings

NEO: The Conference for Neonatology
Feb. 24-27, 2011; Orlando, FL, USA
www.neoconference.com

Workshop on Perinatal Practice Strategies
Apr 15 -17, 2011; Scottsdale, AZ
pedialink.org/cmefinder/index.cfm

CAN/AAP District IX Section on Perinatal Pediatrics 17th Annual Conference
March 4-6, 2011; San Diego CA, USA
www.canneo.org/

SAN/AAP District X Section on Perinatal Pediatrics 25th Annual Conference
May 19-22, 2011; Marco Island, FL USA
www.southeastneo.org/

Recruitment Ads: Page 2

Hypoglycemia and Hyperglycemia in Neonates

By Kaninghat Prasanth, MD, MRCPCH;
Sachin Gupta, MD and Tsu F. Yeh, MD, PhD

It has been almost a century since hypoglycemia in newborn has been recognized as a problem. In spite of innumerable studies, management of hypoglycemia in newborn infants remains a challenge to healthcare providers. In more recent times, hyperglycemia has also been recognized as a problem.

The purpose of this paper is to review the physiology, pathophysiology, clinical signs and symptoms and evidence based management of hypoglycemia and hyperglycemia.

Glucose Metabolism in the Fetus

Glucose metabolism in normal healthy fetus:

The normal healthy fetus receives a constant influx of glucose from the mother. This constant influx provides for basal fetal metabolism. The normal fetoplacental glucose utilization rate is 5 to 6 mg/kg/min. After 27 weeks gestation, this glucose influx also provides for conversion into glycogen, which is deposited mainly in the liver. The fetal glucose levels are maintained by transport of maternal glucose across the placenta along a concentration gradient by a facilitated, carrier-mediated diffusion¹. Under normal circumstances, the source of fetal glucose is almost entirely derived from the maternal glucose pool¹. There is a linear relationship between fetal and maternal glucose levels, with the fetal plasma glucose level being lower than that of the maternal plasma glucose. This linear relationship is maintained during maternal euglycemia, hypoglycemia or hyperglycemia¹.

In a normal healthy fetus, endogenous glucose production is either absent or very negligible. The enzymes for gluconeogenesis are present by the 2-3 months gestation and occurs from lactate, pyruvate or alanine².

The main role of fetal insulin is to ensure glucose is used for growth and storage. Fetal insulin is detected after 13 weeks gestation. The fetal pancreas can release insulin in response to glucose and amino acid by 20 week gestation³. In addition, maternal transfer of amino acids (mainly alanine) have also been shown as a potential source of energy.

Glucose metabolism in abnormal maternal and fetal states

When the supply of glucose to the fetus becomes low and prolonged, the fetus responds by initiating glycogenolysis and later gluconeogenesis. It is important to note that although the fetal glucose is mainly derived from the mother, this is not the only source of energy for the fetus⁴. The fetal brain can use ketones as alternative fuel, especially in situations of prolonged maternal fasting. However, there was one study which suggested that such fetuses whose mothers were ketotic in pregnancy, had developmental delay⁵. In the IUGR fetus, the chronic low glucose levels cause abnormal development of fetal pancreatic beta cells, both in number and in efficiency of insulin secretion. These fetuses also develop resistance to insulin increase hepatic gluconeogenesis. Thus an IUGR fetus can have hypoglycemia due to increased utilization of glucose and low storage or can have hyperglycemia due to increased glucose production due to insulin resistance⁶. In cases of maternal hyperglycemia as result of gestational or insulin-dependent diabetes, fetuses tend to up-regulate insulin secretion.

NEONATOLOGY TODAY

CALL FOR CASES AND OTHER ORIGINAL ARTICLES

Do you have interesting research results, observations, human interest stories, reports of meetings, etc. to share?

Submit your manuscript to: RichardK@Neonate.biz


WE PLACE PEOPLE FIRST

**FULL-TIME PLACEMENT
AND LOCUM TENENS**

Opportunities Nationwide
CHILDREN'S SERVICES

»» **Recruiting**
Pediatric Subspecialties in:

Neonatology
Hospitalists
Critical Care
Emergency Medicine



Physician Trained Placement Specialists

Surgery • Emergency Medicine • Anesthesiology • Radiology • Children's Services • Hospitalists

800.506.8482

www.tivahealthcare.com

childrens@tivahealthcare.com

PERSONALIZED RECRUITMENT SERVICES

Glucose Metabolism in the Immediate Postnatal Period

Normal full term infant

Maternal supply of glucose and nutrients ends with the clamping of the cord. The transition from intra-uterine to postnatal nutrition is initially a catabolic process. (Table 1)

Table 1
Events at birth at term normal infant
Decrease in insulin
Increase in glucagon
Increase in epinephrine
Increase in nor-epinephrine
Increase in cortisol

After birth, there is normal physiological fall in the blood glucose level, and it reaches a nadir by 1-2 hours of age. As a result of changes showed in the Table 1, the glucose levels then rise spontaneously to a steady level by 2-4 hours of age¹. The rate of glucose production in a full term newborn during fasting is 4-6 mg/kg/min. The gradual fall of insulin levels and increase of glucagon, catecholamines and cortisol have the following effects:

1. Hepatic glycogenolysis.
2. Hepatic gluconeogenesis.
3. Lipolysis.
4. Betaoxidation of fatty acids to produce ketone bodies.

Among the catecholamines, epinephrine increases more than norepinephrine in response to hypoglycemia. Epinephrine initially increases hepatic glycogenolysis, followed by sustained increase in hepatic and renal gluconeogenesis.

Preterm infants

In preterm infants, the hormonal response is reduced and there is a lower activity of gluconeogenic enzymes⁷. In addition there is reduced hepatic glycogen stores.

Glucose metabolism in the newborn brain

Glucose is the primary metabolic fuel for the brain. During normoglycemia, 95% of the energy requirements are from glucose, 4% from lactate and less than 1% from ketone bodies (beta-hydroxybutyrate and acetoacetate)⁸. The central nervous system consumes about 30% of the total hepatic glucose output. Studies have shown that a linear relationship exists

between the size of the brain and hepatic glucose production⁹. The bigger the brain size, the more hepatic the glucose output. The mechanism by which the brain regulates hepatic glucose has yet to be elucidated⁹.

The uptake of glucose by the brain is via a carrier-mediated, facilitated diffusion. This process is not energy dependent. The uptake is mediated by a specific protein known as the glucose transporter (GLUT). GLUT 1 & 3 are the main cerebral glucose transporters. The various glucose transporter proteins are summarized in the Table 2.

The glucose taken up by the brain mainly serves three purposes⁸:

1. To be a source of energy for brain metabolism.
2. To provide storage as glycogen in the astrocytes to be used in periods of hypoglycemia.
3. To enter the pentose monophosphate shunt, and provide important substrates for nucleic acid synthesis.

Neuroprotective Mechanisms in Periods of Hypoglycemia

The most vulnerable period for hypoglycemic brain injury is during the transition from intra-uterine to postnatal nutrition. During this period of physiological fall in blood glucose, the brain adapts by various neuroprotective mechanisms. The immature brain is more tolerant of hypoglycemia than the mature brain⁹.

The main neuroprotective mechanisms are:

1. Circulatory changes.
2. Reduction of cerebral metabolism of glucose and use of alternate fuels.

Circulatory changes: The first physiological response of the newborn brain to hypoglycemia is to increase cerebral blood flow (CBF) to satisfy the metabolic needs. In periods of hypoglycemia, previously unperfused capillaries are utilized in an effort to maintain the delivery of glucose¹⁰. Cerebral blood flow in pre-term infants has been shown to increase by approximately 50% if the blood glucose was below a critical level of 30mg/dl, and cerebral blood flow continued to be high up to 30 minutes after the correction of hypoglycemia^{10,11}.

Alternate fuels: During periods of hypoglycemia, the two most important alternate sources of fuel for the brain are lactate and ketone bodies^{8,9}. The glycogen stored in the astrocytes may also contribute as well⁸. During suckling in the immediate post natal period, the concentration of ketone bodies increase and partially substitute glucose to sustain cerebral metabolism¹².

The Effects of Hypoglycemia on Brain

Biochemical Effects

Acute effects - The acute biochemical effects of hypoglycemia becomes evident only when increased CBF is no longer adequate to deliver the required amount of glucose to meet the metabolic needs of the brain^{8,9}.

The main acute affects are:

1. An increase in glycogen mobilisation to increase availability of glucose.
2. A decrease in cerebral metabolic rate
3. An increase in lactate levels.
4. A decrease in amino acid levels and concomitant increase in ammonia.

Table 2		
Glucose Transporter	Primary site	Transport
GLUT 1	Ubiquitous, Erythrocyte, Brain	Glucose
GLUT 2	Liver, Pancreas, Intestine, Kidney	Glucose, Fructose
GLUT 3	Brain	Glucose
GLUT 4	Heart, Muscle, Brain, Adipose	Glucose
GLUT 5	Intestine, Testes, Kidney	Glucose, Fructose
GLUT 6	Brain, Spleen, Leucocyte	Glucose
GLUT 7	Unknown	Unknown
GLUT 8	Testes, Brain	Glucose
GLUT 9	Kidney, Liver	Unknown
GLUT 10	Liver, Pancreas	Glucose
GLUT 11	Heart, Muscle	Glucose, Fructose
GLUT 12	Heart, Muscle, Small intestine	Unknown

Find what you need
with a tap.



 **livescribe**
smartpens

Livescribe smartpens record everything you hear, write or draw. Tap your notes to play back your recordings. Save and share interactive notes to your computer, iPad™ or iPhone™

www.livescribe.com

Get it at



Late effects - Continued decrease in glucose levels lead to neuronal death. The changes include:

1. A marked decrease in cerebral metabolic rate
2. An increase in extracellular glutamate
3. An increase in intracellular calcium
4. An increase in extra cellular potassium
5. A decrease in glutathione levels
6. An increase in free fatty acids

Pathological Effects of Hypoglycemia Brain Injury

Hypoglycemia causes pathological evidence of neuronal injury in the following structures¹³:

- Cerebral cortex
- Hippocampus
- Basal ganglia
- Thalamus
- Brainstem
- Spinal cord

The neuronal necrosis observed were mostly nuclear pyknosis or chromatolysis. Ischemic neuronal injury was a rare feature¹³. Other pathological features include microcephaly, deep and wide sulci, atrophic gyri and periventricular leukomalacia. The only structure seemed to be spared is the cerebellum. Occipital lobe was most severely affected¹³. This predilection for occipital lobe is thought to be due to intensive axonal growth and synaptogenesis resulting in increased glucose demands during the newborn period^{14,15,16}.

Neuro-Imaging in Hypoglycemia

Current evidence suggests that hypoglycemic brain injury causes a specific pattern. Imaging studies, both CT and MRI reveal extensive cortical loss, most marked in the occipital region. The sensitivity of the occipital area to hypoglycemic injury may be explained as above^{15,16}. The parietal cortex also seems to be more susceptible to hypoglycemic injury compared to other areas of the brain.

Table 3 lists the differences in brain injury between hypoglycemia and hypoxic ischemia.

Table 3	
Differences in injury caused by hypoglycemia and hypoxic- ischaemia	
Hypoglycemic injury	Hypoxic- ischemic injury
Superficial distribution of cortical damage - layers 2 & 3	Deeper cortical damage - layers 3,5,6
Pathology- acute degeneration of neurons and glial cells across cerebral cortex - mainly in occipital lobes.	Main involvement of bottom of cerebral sulci or in vascular 'water-shed' area.

Clinical Aspect of Hypoglycemia and Hyperglycemia

Definition

The plasma glucose level of less than 45mg/dl (2.5mmol/l) was originally first observed by Koh et al 22 yrs ago¹⁷. In their study of 17 subjects with ages ranging from 1 day to 12 yr old, they observed changes in the evoked potentials when the blood glucose were 45mg/dl (2.5 mmol/l).

Srinivasan et al suggested the following levels in term infants as hypoglycemia¹⁸:

- < 35 mg/dl, 0-3 hr.
- <40 mg/dl, 3-24 hr.
- < 45 mg/dl, > 24 hr.

More recently 'operational thresholds' have been suggested in managing hypoglycemia. This is discussed later in this paper¹⁹.

Glucose Monitoring

Accurate testing of the levels in the newborn is crucial to the diagnoses and management of hypo or hyperglycemia. The type of sample and the method of analysis are critical in interpreting values. Glucose levels in plasma are 13-18% higher than in whole blood and arterial samples will have 10-15% higher glucose levels than venous samples²⁰. Whole blood with a higher hematocrit has a lower glucose level than whole blood with a lower hematocrit. Because the rate of in-vitro glycolysis is high in neonatal red blood cells, blood samples should be stored on ice or cells separated immediately to prevent falsely low values. Blood glucose values of a blood sample at room temperature drops at the rate of 15-20mg/dl/hr²¹.

The choice of method of measurement of blood or plasma glucose level depends on efficiency and accuracy. Rapid measurement of whole blood glucose is accomplished by glucose oxidase –peroxidase chromogen test strips. The method is hemotocrit dependent. It is important to have any abnormal result (either low or high) confirmed by standard laboratory methods. The

laboratory analysers use different enzymes to measure glucose and are not affected by metabolites or hematocrit levels.

Causes of Hypoglycemia - A Clinico-pathologic Classification (Table 4)

Causes of hypoglycemia can be classified as:

1. Transient Asymptomatic Hypoglycemia
2. Hypoglycemia due to a specific etiology:
 - Inadequate supply of glucose
 - Increased utilization of glucose
 - Unknown mechanism
 - Inborn errors of metabolism or hormonal deficiencies
 - Latrogenic factors

Symptoms of Hypoglycemia

In 1935 Whipple et al described, what is now known as Whipple triad, for the diagnosis of hypoglycemia - presence of characteristic clinical symptoms, confirmation on low plasma glucose level during the clinical symptoms and resolution of clinical symptoms once plasma glucose is normalized.

The main symptoms of hypoglycemia are jitteriness, poor feeding, hypotonia, lethargy, weak cry and seizures.

Diagnostic Evaluation of Infants with Hypoglycemia

The majority of cases of hypoglycemia are seen in infants with low reserve to cope with the immediate periods of fasting or with transient hyper-insulinism, such as infant whose mothers are diabetic. They readily respond to enteral or parenteral supplementation of glucose.

However, occasionally hypoglycemia may be a sign of metabolic or hormonal disorders. The hypoglycemia occurring in such infants is usually severe, refractory or persistent and more likely to have associated clinical features.

Investigations of the cause of hypoglycemia are warranted if the following factors are present:

- A family history of previous infant death or developmental delay
- Persistent or recurrent hypoglycemia
- Symptomatic hypoglycemia in healthy looking term infant with growth appropriate for age
- Hypoglycemia with seizures or altering states of consciousness
- Hypoglycemia requiring glucose delivery of more than 10 mg/kg/min



HELP NEONATOLOGY TODAY GO GREEN!

How: Simply change your subscription from print to the PDF, and get Neonatology Today electronically.
Benefits include: Receive your issue quicker; ability to copy text and pictures; hot links to authors, recruitment ads, sponsors and meeting websites, plus the issue looks exactly the same as the print edition.
Interested? Simply send an email to Subs@Neonate.biz, putting "GO GREEN" in the subject line, and your name, business address, phone and email in the body of the email.

- Hypoglycemia-associated dysmorphic features or other abnormal clinical features (eg. micropenis, exomphalos)

The pertinent investigations and probable conditions are summarized in Table 5. It is important to obtain the samples at the time of hypoglycemia episodes.

Management of Hypoglycemia

Management of hypoglycemia is based on individual patient taking into account the physiologic maturity and pathological influences on the patient. In 2000, Cornblath et al suggested operational thresholds in treatment of hypoglycemia based on 5 broad classification¹⁹:

1. The Term Infant: Healthy term infants born after a normal pregnancy and delivery do not need monitoring of blood glucose. Blood glucose should be measured only if they have clinical manifestations or any new risk of metabolic imbalances emerge.
2. The Infant with signs of hypoglycemia: If any infant show signs of hypoglycemia, treatment should be commenced to maintain plasma glucose above 45mg/dl.
3. Infants with risk factors for compromised metabolic adaptation: Glucose monitoring should be initiated soon after birth, within 2 to 3 hours after birth and before feeding. This should also be done at

point when there is abnormal clinical signs. If the plasma glucose is less than 36mg/dl, close monitoring is recommended with interventions if the plasma glucose remains below this level, if the level does not increase after a feed, or if abnormal clinical signs develop. If the glucose level is below 25mg/dl, intravenous glucose infusion should be given and glucose levels maintained above 45mg/dl. They recommend maintaining plasma glucose level above 60mg/dl in cases of persistent hypoglycemia.

4. Preterm infants: There is no evidence to suggest any lower plasma glucose value for preterm infants.
5. Infants on Parenteral Nutrition: The recommendation is to keep plasma glucose above 45mg/dl. These infants have higher levels of insulin and no significant lipolysis or ketogenesis.

Once the decision to intervene has been taken, the various treatment options are:

1. Continued enteral feed.
2. Intravenous infusion of dextrose- initially a bolus of 200 mg/kg of dextrose, followed by a constant infusion of 8 mg/kg/min. the concentration used is 10% dextrose. This infusion is increased by 2 mg/kg/min, if hypoglycemia persists. Continuous glucose infusion must be started after giving a minibolus to prevent rebound hypoglycemia. Treatment by multiple miniboluses without continuous infusion

Table 4

Pathology	At Risk Group	Mechanism
Inadequate supply of glucose	1. Maternal beta-blocker administration	Suppressed catecholamine response
	2. Preterm infants	Low storage of glycogen Inadequate responses of hormone and enzyme Feeding intolerance
	3. IUGR/ SGA	Low storage of glycogen Inadequate responses of hormone and enzyme Feeding intolerance
	4. Metabolic disease	Defects of enzymes of gluconeogenesis, glycogenolysis or fatty acid oxidation
	5. Sepsis	Feeding intolerance Inadequate hormone or enzyme response
	6. Perinatal stress	Hypoxia, acidosis and alteration in blood pressure stimulate catecholamine release in utero. Hypoxia accelerates glucose use by increasing the rate of anaerobic glycolysis
	7. Hypothermia	Increased use of glucose by tissue. Stimulation of catecholamines, thereby depleting glycogen reserves
Increased utilization of glucose	1. Infant of Diabetic mother	Hyperinsulinism
	2. Maternal use of chlorpropamide or benzothiazide	Hyperinsulinism - Direct stimulation of fetal beta cells
	3. Exchange Transfusion	Hyperinsulinism - Stimulation of insulin secretion by glucose in stored erythrocytes
	4. Beckwith - Wiedemann Syndrome	Hyperinsulinism
	5. Islet cell adenoma/Nesidioblastosis	Hyperinsulinism
	6. Malposition of umbilical artery catheter tip (between T10- L2)	Hyperinsulinism - Glucose flow into celiac axis stimulating insulin secretion
Unknown mechanism	1. Congenital hypopituitarism	Possibly by growth hormone deficiency
	2. Polycythemia - Hyperviscosity Syndrome	Possibly by decrease in plasma volume due to polycythemia leading to reduced availability of glucose
	3. Rhesus hemolytic disease	Possibly by Hyperinsulinism - Reduced glutathione released from hemolysed red cell stimulate Insulin secretion
	4. Trisomy 13 mosaicism	
	5. Congenital adrenal hyperplasia	

Table 5

Sample	Test	Suggestive condition
Blood	Glucose	Confirm hypo/hyperglycemia
Increased utilization of glucose	Hematocrit	Polycythemia
	Serum electrolytes	
	Arterial Blood gas	Acidosis
	Liver function tests	
	Insulin and C-peptide	Hyperinsulinism
	Cortisol	Adrenal disorders
	Growth hormone	Hypopituitarism
	Lactate	Acidosis in various metabolic disorders
	Ketone bodies	Disorders of fatty acid metabolism
	Pyruvate	
	Alanine	
	Free fatty acids	Disorders of fatty acid metabolism
	Ammonia	Urea cycle defects
	Serum amino acids	Disorders of amino acid metabolism
	Total and free carnitine levels	
	Gal - 1 - Put	
Urine	Ketones	
	Organic acids	Disorders of fatty acid metabolism
	Reducing substances	
Ophthalmic evaluation	cataract	Metabolic disorders
Cranial ultrasound/MRI		

Brand et al²² conducted a retrospective study to evaluate the effects of transient hypoglycemia in the first day of life. Their study group were healthy large for gestational age (LGA) infants born to non-diabetic mothers. Blood glucose measurements were done at 1, 3 and 5 hours of age. Their definition of hypoglycemia was blood glucose less than 2.2 mmol/L (40mg/dl) in the first hour of life and blood glucose less than 2.5 mmol/l (46mg/dl) subsequently. These infants were tested using the Denver Developmental Scale, non-verbal intelligence test, and the child behaviour check list. This study suggested that transient mild hypoglycemia (1.5-2 mmol/L) in healthy term LGA infants does not appear to be harmful to psychomotor development at age of 4 years.

Duvanel et al²³ conducted a prospective study involving small-for-gestational-age (SGA) preterm infants. They compared infants with blood glucose levels less than 2.6 mmol/l to a similar group who maintained normoglycemic. Any infant with less than 2 mmol/l was treated with intravenous 10% dextrose at the rate of 5 to 9 mg/kg/minute. They conducted neurodevelopmental and neurological examinations from 6, 12 and 18 months of corrected gestational age. Further psychometric tests were performed at 3.5 and 6 years of age.

Their study concluded that:

1. The incidence of hypoglycemia in SGA preterm infants was 73%, more common than previously thought.
2. Head circumference at 12, 18 months and at 5 years was significantly reduced in infants who had repetitive hypoglycemia. (6 episodes or more).
3. Psychometric tests at 6, 12 and 18 months were similar between infants with repetitive hypoglycemia (6 episodes or more) and the control group. However, perceptible performance scale and motricity index were decreased in repetitive hypoglycemia group at 3.5 years of age.
4. Infants with recurrent moderate hypoglycemia (blood glucose between 0.6 to 1.6 mmol/L) had lower neurodevelopmental scores than the group with a single unique severe episode of hypoglycemia at 3.5 and 5 years of age.

Lucas et al conducted a multicentric study involving 661 preterm infants (weighing less than 1850g). The authors determined that the plasma glucose levels every six hours for the first 48 to 72 hours of age²⁴. They concluded that:

1. The incidence of hypoglycemia below 1.6 mmol/l occurred in 28% of the infants.
2. Moderate hypoglycemia (less than 2.6 mmol/L) occurred in 67% of infants.
3. Plasma glucose below 2.6 mmol/l resulted in reduction of motor and mental development scores at 18 months.
4. The deficit increased with the number of days of hypoglycemia.

is not recommended. Glucose infusion can be increased to 12-14mg/kg/min, after which further increases may produce fluid overload, venous thrombosis. Any dextrose infusion having a concentration of more than 10% should be given through a central access eg. UVC, PCVC. Once normoglycemia is achieved glucose infusion should be decreased gradually by 2mg/kg/min, while increasing enteral feeds.

3. Hydrocortisone - If the plasma glucose levels are not above 40mg/dl or if hypoglycemia recurs after intravenous glucose infusion of 12mg/kg/min, then hydrocortisone 10mg/kg/day in 2 divided doses given, IV, IM or orally. Hydrocortisone acts by the following mechanisms: reduces peripheral glucose utilization, increases the effects of exogenous glucagon and enhances gluconeogenesis. Hydrocortisone is continued for around 72 hours after stopping intravenous fluids.
4. Epinephrine - If hypoglycemia does not respond to the above-mentioned measures, then a trial of epinephrine is suggested. Initially, a subcutaneous injection is given, followed by intravenous infusion. Epinephrine acts by mobilizing stored fuels by glycogenolysis, gluconeogenesis, lipolysis, augmentation of glucagon action and suppression of insulin secretion. Hence epinephrine is particularly useful in infants with hyperinsulinism.

5. Glucagon - This is hardly used except if the infant has glucagon deficiency. There may be a use in diagnosing cases of hepatic glycogen storage disorders.
6. Diazoxide - This is a non-diuretic thiazide which inhibits pancreatic insulin secretion, hence often effective in infants with hyperinsulinism.
7. Human growth hormone - this is effective in infants with hypoglycemia secondary to growth hormone deficiency.
8. Somatostatin- this is mainly confined to pre-operative control in infants with suspected beta cell nesidioblastosis - adenoma spectrum.
9. Pancreatectomy - In cases of beta cell nesidioblastosis- adenoma spectrum, partial or full pancreatectomy may be effective if medical therapy fails.

Neonatal Hypoglycemia and Neurodevelopment

All the controversies about hypoglycemia and its treatment aim at minimizing the final outcome -- neurodevelopmental disability. Several studies have tried to establish a 'safe' level of blood glucose above which there is no risk of neurodevelopmental disability. Although all of these studies have contributed to our understanding of hypoglycemia and long-term neuro-developmental disability, only a few are discussed here.

Conclusion

In spite of the numerous studies, the extent of neuro-developmental impairment caused by hypoglycemia is still uncertain and many questions remain to be answered⁴³.

Hyperglycemia

The degree of prematurity plays a central role in incidence of hyperglycemia. Hyperglycemia is most commonly seen in preterm infants less than 30 week gestation, and in their first day of life²⁵. There was a highly significant trend toward an increasing risk of hyperglycemia with decreasing body weight, such that the risk of hyperglycemia among infants weighing less than 1,000 g was 18 times greater than the risk among infants weighing more than 2,000 g²⁵.

Definition of Hyperglycemia

As with hypoglycemia, the threshold value of blood glucose used to diagnose hyperglycemia is variable.

The physiological threshold of blood glucose is above 125 mg/dl (7 mmol/L); the rationale being that the blood glucose levels in utero and in term infants rarely have blood glucose above 7 mmol/L.

Functional or interventional threshold - Most neonatologists would consider intervention when the blood glucose is above 180mg/dl (10 mmol/L).

Possible Causes and Pathophysiological Effects of Hyperglycemia

Causes of Hyperglycemia

1. **Prematurity** - prematurity predisposes to hyperglycemia by various mechanisms. The 'insulin' secreted by premature infants is actually a range of proinsulin polypeptides with the majority of the 'insulin' having only a tenth of the biological activity of mature insulin²⁵. The tissues of preterm infants are also relatively resistant to insulin.
2. **Sepsis and Stress** - Hyperglycemia may be the first sign of infection. Infants experiencing stress as a result of sepsis or surgery have increased levels of catecholamines which causes hyperglycemia. Hyperglycemia is also seen in infants with an episode intracerebral bleed, because of the lower glucose consumption occurring during this bleeding episode.
3. **Parenteral Infusion** - Glucose delivery in excess of 10mg/kg/min especially in preterm infants are likely to cause high blood glucose levels.
4. **Medications** - Steroids, inotropes, theophylline all have been shown to increase blood glucose levels.
5. **Factitious** - Occasionally spurious levels are seen if venous samples are drawn when a glucose infusion is being run from down the vein, as it is also the case when a sample is taken from arterial line running dextrose infusion.
6. **Transient or Permanent Diabetes Mellitus.**

Pathophysiological effects of hyperglycemia

Hyperglycemia will lead to osmotic diuresis, cause changes in osmolality of the plasma, which in turn lead to effects such as electrolyte disturbances, dehydration and intraventricular bleed. Plasma osmolality increases by 1 mosmol/L for each 18 mg/dL increase in plasma glucose concentration²⁵. Osmotic diuresis is more likely at blood glucose levels above 360 mg/dl²⁵. Hey et al suggested that even at 2% glucosuria, the additional osmolal load is extremely unlikely to cause osmotic diuresis²⁵.

Potential Adverse Effects of Hyperglycemia

Over the years various workers have recognized the deleterious effects of hyperglycemia. Hyperglycemia may be associated with higher mortality, higher incidence of IVH, infection, NEC, ROP, fungal infection and poor neurodevelopment outcome²⁹⁻³⁶.

Management of Hyperglycemia

Although there is no definite value, most neonatologists would consider intervention at values of 180-200 mg/dl. The management of hyperglycemia is essentially maintaining a fine balance between providing enough glucose for growth of the infant and preventing the deleterious effects of hyperglycemia. Equally important is the recognition that hyperglycemia may be the first sign of sepsis. The salient features of management are:

1. **Investigating and treating underlying conditions** - Sepsis, stress, pain, hypoxia and medications are all known to induce hyperglycemia and it is prudent to correct them quickly.
2. **Optimizing nutrition** - Starting enteral feeds if possible, however, small the amount improves glycemic control. Also there may be a benefit by increasing amino acid infusion in the parenteral nutrition.
3. **Optimizing glucose delivery** - A stable infant needs about 6 mg/kg/min of glucose. An additional 2 mg/kg/min is needed if the infant is unwell. A glucose infusion above 12 mg/kg/min is counter-productive and is unnecessary.
4. **Insulin therapy** - Persistent hyperglycemia, in spite of the above measures, warrants treatment with insulin. We routinely start a dose of 0.05U/kg/hr, and monitor blood glucose every 2 hours. As evident from the NIRTURE study²⁶, there is little clinical benefit in prophylactic early insulin therapy along with glucose infusion.

Neonatal Diabetes Mellitus

Neonatal diabetes mellitus is a very rare but well recognized condition having an incidence of 1 in 400,00- 500,000 newborns²⁷.

Neonatal Diabetes Mellitus (NDM) is defined as persistent hyperglycemia occurring in the first month of life, lasting for at least 2 weeks, and requiring insulin. Some have suggested the age of onset be extended to the first 6 months of age and the condition to be renamed as 'Congenital Diabetes Mellitus.'

Clinical Features

The majority of infants with NDM have IUGR, not surprisingly given the role fetal insulin has on fetal growth. The clinical features are hyperglycemia, IUGR/ SGA, failure to thrive, dehydration, ketoacidosis and coma.

Therapy with insulin corrects the hyperglycemia and results in catch-up growth. No dysmorphic features have been associated with NDM, and it is not possible to differentiate between Transient NDM and Permanent NDM clinically²⁶.

1. **Transient Neonatal Diabetes Mellitus (TNDM)**²⁶ - Fifty to sixty percent of NDM are transient. The insulin dependence resolves in 3-4 months of age in majority of cases. The following mutations have been observed in TNDM:
 - Gene mutation on chromosome (6-70%)
 - ABCC8 mutation (13%)
 - KCNJ11 mutation (10%)

Infants with TNMD have a risk of relapsing into a permanent diabetic state around adolescence or adulthood.

2. **Permanent Neonatal Diabetes Mellitus (PNMD)**²⁶ - 40-50%. As the name suggests, the hallmark of PNMD is hyperglycemia without resolution of insulin dependence. Multiple gene defects have been associated with this condition with about 50% of cases linked to potassium channel mutation.

Treatment of Neonatal Diabetes Mellitus

Prompt correction of dehydration and electrolyte imbalances, Insulin therapy and high calorie diet are the mainstay of treatment. Depending on the gene mutation, a few of these cases may also be treated by sulphanyl ureas. However these are best left to specialized centers who are experienced in managing such patients. Given the complex nature of gene mutations and inheritance, all families must be offered genetic counseling.

Supported in part from National Health Research Institute (NHRI-EX-99-9818PI) Taiwan.

References

1. Polin and Fox. Fetal and Neonatal Physiology.
2. R  ih   NC, Lindros KO. Development of some enzymes involved in gluconeogenesis in human liver. *Ann Med Exp Biol Fenn.* 1969;47(2):146-50.
3. Mitanchez D. Glucose regulation in preterm newborn infants. *Horm Res.* 2007;68(6):265-71. Epub 2007 Jun 20. Review.
4. Avery G.B et al. Neonatology- Pathophysiology & Management of the Newborn.
5. Rozance PJ, Hay WW Jr. Describing hypoglycemia--definition or operational threshold? *Early Hum Dev.* 2010 May;86(5):275-80. Epub 2010 May 31.
6. Hume R, Burchell A, Williams FL, Koh DK : Glucose homeostasis in the newborn.. *Early Hum Dev.* 2005 Jan;81(1):95-101. Epub 2004 Nov 19. Review.
7. Yager JY. Hypoglycemic injury to the immature brain. *Clin Perinatol* 29(2002) 651-674.
8. Volpe JJ. Neurology of the Newborn: Hypoglycemia and Brain Injury
9. Malcolm L, Frank Fetal and Neonatal Neurology and Neurosurgery.
10. Skov L, Pryds O. Capillary recruitment for preservation of cerebral glucose influx in hypoglycemic, preterm newborns: evidence for a glucose sensor? *Pediatrics.* 1992 Aug;90(2 Pt 1):193-5
11. Pryds O ,Chritensen N J, Friis-Hansen B. Increased Cerebral Blood Flow and plasma epinephrine in Hypoglycaemic preterm infants. *Pediatrics* 1990.
12. Vannucci RC, Vannucci SJ. Glucose metabolism in the developing brain *Seminars in Perinatology*, Volume 24, Issue 2, April 2000, Pages 107-115.
13. Anderson JM, Milner RD, Strich SJ. Effects of neonatal hypoglycemia on the nervous system: a pathological study. *J Neurol Neurosurg Psychiatry* 1967 (30) 295-310.
14. Alkalay AL, Flores-Sarnat L, Sarnat HB, Moser FG, Simmons CF. Brain imaging findings in neonatal hypoglycemia: case report and review of 23 cases. *Clin Pediatr (Phila).* 2005 Nov-Dec;44(9):783-90. Review.
15. Traill Z, Squier M, Anslow P. Brain imaging in neonatal hypoglycaemia. *Arch Dis Child Fetal Neonatal Ed.* 1998 Sep;79(2):F145-7.
16. Barkovich AJ, Ali FA, Rowley HA, Bass N. Imaging patterns of Neonatal Hypoglycemia. *AJNR Am J Neuroradiol.* 1998 Mar;19(3):523-8.
17. Koh TH, Aynsley-Green A, Tarbit M, Eyre JA. Neural dysfunction during hypoglycaemia. *Arch Dis Child.* 1988 Nov;63(11):1353-8.
18. Srinivasan G, Pildes RS, Cattamanchi G, Voora S, et al: Clinical and laboratory observations: Plasma glucose values in normal neonates- a new look, *J Pediatr* 109:114-117, 1986.
19. Cornblath M, Hawdon JM, Williams AF, Aynsley-Green A, Ward-Platt MP, Schwartz R, Kalhan SC : Controversies regarding definition of neonatal hypoglycemia: suggested operational thresholds.. *Pediatrics.* 2000 May;105(5):1141-5. Review
20. Beardsall K. Measurement of glucose levels in the newborn. *Early Human Development.* 86 (2010) 263-267.
21. Yeh T.F. Neonatal Therapeutics. 2nd Edition 1991
22. Brand PL, Molenaar NL, Kaaijk C, Wierenga WS. Neurodevelopmental outcome of hypoglycaemia in healthy, large for gestational age, term newborns. *Arch Dis Child.* 2005 Jan;90(1):78-81.
23. Duvanel CB, Fawer CL, Cotting J, Hohlfeld P, Matthieu JM. Long-term effects of neonatal hypoglycemia on brain growth and psychomotor development in small-for-gestational-age preterm infants. *J Pediatr.* 1999 Apr;134(4):492-8.
24. Lucas A, Morley R, Cole TJ..Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia. *BMJ.* 1988 Nov 19;297(6659):1304-8.
25. Hays E. Hyperglycemia and the very preterm baby. *Seminars in Fetal & Neonatal Medicine* (2005) 10, 377-387.
26. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, Vanhole C, Palmer CR, van Weissenbruch M, Midgley P, Thompson M, Thio M, Cornette L, Ossueta I, Iglesias I, Theyskens C, de Jong M, Ahluwalia JS, de Zegher F, Dunger DB. Early insulin therapy in very-low-birth-weight infants. *N Engl J Med.* 2008 Oct 30;359(18):1873-84.
27. Von M  hlendahl KE, Herkenhoff H. Long-term course of neonatal diabetes. *N Engl J Med.* 1995 Sep 14;333(11):704-8.
28. Aguilar-Bryan L, Bryan J. Neonatal diabetes mellitus. *Endocr Rev.* 2008 May;29(3):265-91. Epub 2008 Apr 24.
29. Alexandrou G, Ski  ld B, Karl  n J, Tessma MK, Norman M, Ad  n U, Vanp  e M. Early hyperglycemia is a risk factor for death and white matter reduction in preterm infants. *Pediatrics.* 2010 Mar;125(3):e584-91. Epub 2010 Feb 22.
30. van der Lugt NM, Smits-Wintjens VE, van Zwieten PH, Walther F.J. Short and long term outcome of neonatal hyperglycemia in very preterm infants: a retrospective follow-up study. *BMC Pediatr.* 2010 Jul 20;10:52..
31. Heimann K, Peschgens T, Kwiecien R, Stanzel S, Hoernchen H, Merz U. Are recurrent hyperglycemic episodes and median blood glucose level a prognostic factor for increased morbidity and mortality in premature infants <=1500 g? *J Perinat Med.* 2007;35(3):245-8.
32. Hays SP, Smith EO, Sunehag AL. Hyperglycemia is a risk factor for early death and morbidity in extremely low birth-weight infants. *Pediatrics.* 2006 Nov;118(5):1811-8.
33. Kao LS, Morris BH, Lally KP, Stewart CD, Huseby V, Kennedy KA. Hyperglycemia and morbidity and mortality in extremely low birth weight infants. *J Perinatol.* 2006 Dec;26(12):730-6.
34. Ertl T, Gyarmati J, Ga  l V, Szab   I. Relationship between hyperglycemia and retinopathy of prematurity in very low birth weight infants. *Biol Neonate.* 2006;89(1):56-9.
35. Blanco CL, Baillargeon JG, Morrison RL, Gong AK Hyperglycemia in extremely low birth weight infants in a predominantly Hispanic population and related morbidities. *J Perinatol.* 2006 Dec;26(12):737-41. Epub 2006 Aug 24.
36. Manzoni P, Castagnola E, Mostert M, Sala U, Galletto P, Gomirato G Hyperglycaemia as a possible marker of invasive fungal infection in preterm neonates. *Acta Paediatr.* 2006 Apr;95(4):486-93.
37. Garg R, Agthe AG, Donohue PK, Lehmann CU. Hyperglycemia and retinopathy of prematurity in very low birth weight infants. *J Perinatol.* 2003 Apr-May;23(3):186-94.
38. Caraballo RH, Sakr D, Mozzi M, Guerrero A, Adi JN, Cers  simo RO, Fejerman N. Symptomatic occipital lobe epilepsy follow-

Evidence-based Neonatology

2-5 June 2011, Stockholm, Sweden

Register today - www.EBNEO.org

- ing neonatal hypoglycemia. *Pediatr Neurol.* 2004 Jul;31(1):24-9.
39. Walid A, Salhab, Myra H, Wyckoff, Abbot R, Laptook, Jeffrey M, Perlman : Initial Hypoglycemia and Neonatal Brain Injury in Term Infants With Severe Fetal Acidemia. *Pediatrics* 2004; 114: 361-366.
 40. Vannucci RC, Vannucci SJ: Hypoglycemic brain injury. *Semin Neonatol* 2001;6:147-155.
 41. Filan PM, Inder TE, Cameron FJ, Kean MJ, Hunt RW. Neonatal hypoglycemia and occipital cerebral injury. *J Pediatr.* 2006 Apr;148(4):552-5. Review.
 42. Nachum Z, Ben-Shlomo I, Rakover Y, Weiner E, Shalev E. Early brain atrophy in persistent hyperinsulinemic hypoglycemia of infancy. *J Pediatr.* 2002 Nov;141(5):706-9.
 43. Boluyt N, van Kempen A, Offringa M. Neurodevelopment after neonatal hypoglycemia: a systematic review and design of an optimal future study.
 44. Kairamkonda VR, Khashu M. Controversies in the management of hyperglycemia in the ELBW infant. *Indian Pediatr.* 2008 Jan;45(1):29-38. Review
 45. Cowett R M. Neonatal hypoglycemia: A little goes a long way *The Journal of Pediatrics* Issue: Volume 134(4), April 1999, pp 389-391
 46. Coulthard M G, Hey E N. Renal processing of glucose in well and sick neonates. *Arch Dis Child Fetal Neonatal Ed* 1999; 81: F92-98.
 47. Hall N J, Peters M, Eaton S et al. Hyperglycemia is associated with increased morbidity and mortality rates in neonates with necrotizing enterocolitis. *J Pediatr Surg* 2004; 39: 898-901.
 48. Stonestreet BS, Rubin L, Pollak A, Cowett RM, Oh W. Renal functions of low birth weight infants with hyperglycemia and glucosuria produced by glucose infusions. *Pediatrics.* 1980 Oct;66(4):561-7.
 49. Sinclair JC, Bottino M, Cowett RM. Interventions for prevention of neonatal hyperglycemia in very low birth weight infants. *Cochrane Database Syst Rev.* 2009 Jul 8;(3):CD007615. Review.
 50. Deshpande S, Ward Platt M. The investigation and management of neonatal hypoglycaemia. *Semin Fetal Neonatal Med.* 2005 Aug;10(4):351-61.
 51. WHO review of neonatal hypoglycemia.
 52. Kahler SG. Metabolic Disorders Associated With Neonatal Hypoglycemia. *Neoreviews* Sept. 2004 ; Vol 5. No.9.
 53. Kalhan S, Parimi P. Gluconeogenesis in the Fetus and Neonate. *Seminars in Perinatology*, Vol 24, No 2 (April), 2000: p94-106.
 54. Lilien LD, Pildes RS, Srinivasan G. Treatment of neonatal hypoglycemia with minibolus and intravenous glucose infusion. *Journal of Pediatrics* 97: 295-298, 1980.
 55. Churchill JA, Berendes HW, Nemore J. Neuropsychological deficits in children of diabetic mothers. *Am J Obstet Gynecol* 1969;105:257.
 56. Polak M, Cavé H. Neonatal diabetes mellitus: a disease linked to multiple mechanisms. *Orphanet J Rare Dis.* 2007 Mar 9;2:12.
 57. Cornblath M, Ichord R: Hypoglycemia in the Neonate. *Semin Perinatol.* 2000 Apr;24(2):136-49. Review.
 58. Hay WW Jr, Raju TN, Higgins RD, Kalhan SC, Devaskar SU.: Knowledge gaps and research needs for understanding and treating neonatal hypoglycemia: workshop report from Eunice Kennedy Shriver National Institute of Child Health and Human Development.
 59. Alkalay AL, Flores-Sarnat L, Sarnat HB, Farber SJ, Simmons CF. Plasma glucose concentrations in profound neonatal hypoglycemia. *Clin Pediatr (Phila).* 2006 Jul;45(6):550-8.
 60. Louik C, Mitchell AA, Epstein MF, Shapiro S. Risk factors for neonatal hyperglycemia associated with 10% dextrose infusion. *Am J Dis Child.* 1985 Aug;139(8):783-6.

NT

*Kaninghat Prasanth, MD, MRCPCB
Division of Neonatology
Department of Pediatrics
John H. Stroger Jr. Hospital of Cook
County, Chicago
Chicago, IL USA*

*Sachin Gupta, MD
Division of Neonatology
Department of Pediatrics
John H. Stroger Jr. Hospital of Cook
County, Chicago
Chicago, IL USA*

Corresponding Author

*T.F. Yeh, MD, PhD
Division of Neonatology
Department of Pediatrics
John H. Stroger Jr. Hospital of Cook
County
1902 W. Harrison St.
Chicago, IL 60612 USA*

and

*China Medical University
91 Hsieh Shih St.
Taichung, Taiwan
or
Taipei Medical University
Wu-Shin St. Taipei, Taiwan*

tsufuhy@yahoo.com

APRIL MEETING FOCUS

Workshop on Perinatal Practice Strategies

*Sponsored by the AAP Section on Perinatal
Practices and AAP*

April 15-17, 2011; Scottsdale, AZ USA
pedialink.org/cmefinder/index.cfm

Speakers include:

Kurt H. Albertine, PhD; Wanda Denise Barfield, MD, MPH, FAAP; Robert W. Block, MD, FAAP; Carl L. Bose, MD, FAAP; James W. Collins MD, MPH, FAAP; Mark Del Monte, JD; Dmitry Dukhovny, MD, MPH; Kimberly Dawn Ernst, MD, MSMI, FAAP; Marilyn Barnard Escobedo, MD, FAAP; John V. Hartline, MD, FAAP; William J. Keenan, MD, FAAP; George A Little, MD, FAAP; Gilbert I. Martin, MD, FAAP; Richard A. Molteni MD, FAAP; Lu-Ann Papile MD, FAAP; Stephen Arthur Pearlman, MD, FAAP; DeWayne M. Pursley, MD, MPH, FAAP; Tonse N. K. Raju, MD, DCH, FAAP; Rangasamy Ramanathan, MD, FAAP; Rita Marie Ryan, MD, FAAP; Clara Hyun-Jung Song, MD, FAAP; Michele Catherine Walsh, MD, FAAP; and John A. F. Zupancic, MD, ScD, FAAP

Concurrent Session Topics:

Beyond Coding: Making Codes Matter to Payors; Newer Methods of Non-Invasive Ventilation in Newborns; Work/Life Balance - Finding Your "Center"; The Virtual Team in the NICU: Social Media Update; New NRP Guidelines; Using Evidence to Develop Clinical Guidelines; Understanding Budgets and NICU Finance; Beyond Coding: Making Codes Matter to Payors; Newer Methods of Non-Invasive Ventilation in Newborns; New and Improved or New and Disproved: Technology Assessment and Your NICU; Exploring and Evaluating Practices in Neonatology; Growth and Development of the Senior Neonatologist; Neonatology QUICK TIPS: QUality, Improvement, Certification, Knowledge, Teaching, Investigation, Patient Care, Scholarship; What Certificate Holders Need to Know about MOC; The Virtual Team in the NICU: Social Media Update; New NRP Guidelines; Using Evidence to Develop Clinical Guidelines; and Understanding Budgets and NICU Finance

Plenary Sessions:

L. Joseph Butterfield Lecture - Global Neonatology and You; Setting the Stage: Getting From Idea to Implementation; New Insights into the Racial Disparity in Birth Outcome: A Life-course Perspective; Health Care Reform and Neonatology; Health Care Reform and the AAP; SOPPe "Perinatal Section at Work"/Trainee and Early Career Neonatologists Group (TECaN) Report; Maintenance of Certification: Realities for the Practitioner; Committee on Fetus and Newborn (COFN); The Role of Non-Invasive Ventilation in Newborns; Brain Injury in Chronically Ventilated Preterm Neonates: and Collateral Damage Related to Ventilation Strategy and Underlying Mechanisms

Specialty Course:

- Special Networking Opportunity for Non-Physician Coding and Billing Staff
- Coding Seminar

Visit us at **NEO 2011**
in **Orlando, FL** – Feb 24-27

RetCam™

Ophthalmic Imaging in the NICU and PICU

Easy to do...More important than ever



RetCam Digital Imaging makes it possible for your staff to capture photographs of the pediatric retina in the NICU and PICU. The simple procedure allows you to image patients with critical needs, then transfer the images electronically to the ophthalmologist for essential review and follow up. With RetCam imaging, you are equipped with advanced technology to facilitate ophthalmic care for your tiniest patients.

RET-CAM™ TRAINING MODULES

Now your staff can learn about ocular anatomy, the retinal fields of view used for clinical evaluation, and photographic imaging technique in a step-by-step training program available on the Clarity website. These modules can be reviewed prior to RetCam installation and as an instructional course for your clinicians and staff.

VISIT OUR BOOTH #419

Let us show you how to capture a digital image with the new ergonomic hand piece. Receive a free 2GB USB drive with a RetCam demonstration.



5775 West Las Positas Blvd.
Pleasanton, CA 94588-4084
(925) 463-7984 main
(925) 251-0078 fax
www.claritymsi.com

'CAN' Syndrome (Cord-Around-the-Neck Syndrome)

By Morarji Peesay, MD; Nitin Mehta, MBBS

To date, I do not think anyone has coined the term "CAN Syndrome." Many of us are very well-acquainted with the term "Cord-Around-the-Neck," but have not yet thought of it as an actual syndrome. The CAN Syndrome is a complex syndrome which is similar to the act of one being strangulated at varying intensities. We as neonatologists are well aware of the signs and symptoms associated with CAN, and manage it routinely in the NICU. I think it deserves attention to heighten its awareness, since it is such a commonly encountered condition.

To those who practice obstetrics, it seems that this delicate thread (the umbilical cord) all too often becomes wrapped around the newborn's neck. Much like a hangman's noose, the nuchal cord is often blamed for problems that are encountered during delivery, and is sometimes cited as a major cause of fetal distress and perinatal mortality. The actual significance that a nuchal cord has on the outcome of an infant is controversial.

So, could the nuchal cord really affect the outcome of delivery and have long-term effects on the infant?

As neonatologists, we have encountered CAN scenarios multiple times. These infants look pale, dusky, hypovolemic, and most often need some resuscitation (we frequently admit them in NICU for fluid resuscitation). The basic work-up of these infants has shown that they are mildly acidotic and anemic. They may also have mild respiratory distress manifested by minimal retraction, grunting, and flaring. Those infants who have the cord-around-the-neck may also have petechiae above the cord entanglement, usually seen on the face and neck and upper part of chest. They may also be somewhat obtunded and have a stupor with a low tone. They are slow to feed and may also have feeding difficulties transiently.

All these features suggest to me that these infants may go into transient encephalopathy which may lead to long-term complications that we do not know.

To-date, and to my knowledge, there are no EEG findings in these infants. There are no studies assessing the neurological status of these infants or their Sarnat scoring. Long-term effects of oxygen deprivation, acidosis, and hypovolemia secondary to CAN are unknown.

I define the CAN Syndrome as a cluster of cardio-respiratory and neurological signs and



A - Fetal scan showing Doppler flow of umbilical cord around the neck; B, D and E - 3D image of fetal scan showing CAN; C and E - Fetal scan showing CAN in 3D. Photos as courtesy Maryland Perinatal Associates.

symptoms that occur secondary to the initial wrapping of the cord around the neck.

The cluster of symptomatology includes: pallor (anemia), duskiness, hypovolemia, acidosis, mild respiratory distress, petechiae on the face, neck and upper chest, stupor, hypotonic, feeding difficulties.

It is a transient phenomenon, but may have long-term effects in the infant. These could be related to the prolonged strangling of the tight cord-around-the-neck.

There may be long-term effects related to prolonged and tight cord round the neck keeping in mind that it is similar to strangulation of young newborn.

Recognizing this as a syndrome has several advantages:

1. It will heighten the awareness of such a cluster of signs and symptoms related to CAN.
2. It allows us to focus on the long-term neurological aspects of prognosis, and prognosticate better after further studies.
3. it might bring better diagnostic modality and management in the future.
4. It will bring recognition to the infants inadvertently subjected to CAN.

Twenty-five percent of pregnant women present with nuchal cords, and the majority of them don't have significant problems related to it. Despite the good prognosis in most of the cases, some studies demonstrate that the

“I define the CAN Syndrome as a cluster of cardio-respiratory and neurological signs and symptoms that occur secondary to the initial wrapping of the cord around the neck.”

presence of a nuchal cord is associated with variable fetal heart rate deceleration, decreased fetal movement, umbilical arterial metabolic acidemia, neonatal anemia, and, in extreme situations, intrauterine fetal demise. Antenatally, a nuchal cord can sometimes be detected by ultrasonography, but no action is required by the obstetrician. In no study was it possible to distinguish between a loose and a tight cord on ultrasound. According to Larson, nuchal entanglement increases from 6% at 20 weeks of gestation to 30% at, and around 40 to 42 weeks.

The most common fetal effects of nuchal cords are fetal heart rate decelerations during labor or a change in fetal behavior prenatally.

The presence of two or more loops is estimated to affect between 2-8% of all pregnancies. Obstetricians routinely check for nuchal cords as they deliver the baby. If they feel it, they can slip the cord over the baby's head. Sometimes, if the cord is tightly wrapped, it is clamped and cut before the shoulders are delivered. However, recent studies show that there is little reason to check for a cord, because cutting it cuts off the oxygen that the placenta is supplying and outcomes are better if the baby is delivered. The cord, then, is no longer compressed after the birth, and will continue to provide oxygen for a few more minutes. This is only possible if the delivery is rapid. The cord may become coiled around various parts of the body of the fetus, usually around the neck. Some suggest that Nuchal cord is caused by movement of the fetus through a loop of cord. Nuchal cord has been associated with labor induction and augmentation, prolonged second stage of labor, and fetal heart rate abnormalities. Nuchal cords very rarely cause fetal demise, and are not an

intrinsic reason for intervention. The importance of nuchal cord vis a vis the management of third trimester pregnancy and labor has been debated for many years.

Studies were unable to demonstrate any association between nuchal cords and maternal age, race, parity, pre-pregnancy weight, or weight gain. Infant sex was not significantly associated with nuchal cords, either.

The average umbilical cord length is 50 to 58 cm, with longest reported cord measuring 175 cm. The length of the umbilical cord predisposes an infant to a nuchal cord. Longer cords tend to become looped around the neck. Nuchal coiling can occur in shorter cords, however, in which case the cord tends to be more tightly wrapped around the infant's neck.

In 1995, Larson had studied the intrapartum complications associated with multiple nuchal cord entanglement. He concluded that the group with four or more loops involved had significantly lower birth weight, more episodes of severe variable and late decelerations, meconium, and a higher incidence of operative delivery. However, if signs of fetal discomfort -- such as decreased fetal movement or persistent fetal heart variable decelerations, or even signs of fetal distress like repeated late decelerations -- are present, operative intervention is recommended.

Although the presence of a single nuchal cord does not require changes in the management of the pregnancy, does the prenatal detection of multiple loops alter the management?

Does CAN Syndrome have long-term effects? Does releasing tight cord around the neck prior to delivery of the infant minimize short-term or long-term effects?

Although some authors seem to suggest that those newborns delivered with four or more nuchal loops around the neck are at a higher risk to develop complications. Does tight cord around matter for long-term neurological sequel rather than multiple loops around the neck? A long-term follow-up of these infants may shed some light.

References

- Larson, J.D., Rayburn, W.F., Harlan, V.L.(1997). Nuchal cord entanglement and gestational age. Am J Perinatol. 14(9): 555-557.

- Larson, J.D., Rayburn, W.F., Crosby, S., Thurnau, G.R.(1995). Multiple nuchal entanglements and intrapartum complications. Am J Obstet Gynecol 173(4): 1228-1231.
- Hankins, G.D.V., Snyder, R.R., Hauth, J.C., Gilstrap III, L. C., Hammond, T.(1987). Nuchal cords and neonatal outcome. Obstet. Gynecol. 70(5): 687 - 691.
- Tejani N.A., Mann, L.I., Sanghavi, M., Bhakthavathsalan A., Weiss, R.(1977). The association of umbilical cord complications and variable decelerations with acid-base findings. Obstet Gynecol 49: 159-162.
- Steinfeld, J.D., Ludmir, J., Eife, S., Robbins, D., Samuels, P.(1992). Prenatal detection and management of quadruple nuchal cord. J Reprod Med 37(12): 989-991.

NT

Corresponding Author



Morarji Peesay, MD, FAAP
Neonatal Attending
Georgetown University Hospital
3800 Reservoir Rd. NW
Washington, DC 20007 USA
Tel: 301.774.8758; Fax: 301.774.2425
peesay@yahoo.com



Nitin Mehta, MBBS
Georgetown University Hospital
3800 Reservoir Road, NW
Main Hospital Building
3rd Floor, Room M3400
Washington, DC 20007 USA



Sign up for a free membership at 99nicu, the Internet community for professionals in neonatal medicine. Discussion Forums, Image Library, Virtual NICU, and more...!

www.99nicu.org

Global Neonatology Today: A Monthly Column: Commentary Concerning the Millennium Development Goals: Pros and Cons

By Dharmapuri Vidyasagar, MD, FAAP, FCCM

Despite the world-wide acceptance of the Millennium Development Goals, and their target dates and the indicators, there is no lack of debate on the pros and cons of the concept and the implementation process of MDGs by 2015.

The supporters believe that the Millennium Development Goals (MDGs) are indeed important for the progress of the people around the world. The critics believe that the goals for global development are too narrow. Here are the important points in favor and against the concept of MDGs.

THE PROS

1. MDGs, even though somewhat narrowed to eight major goals, MDGs motivate governments to work toward improving and achieving targets.
2. Secondly, whether the countries reach the set Goals or not by 2015, they would have stimulated leadership towards the betterment of their countries.
3. The above two points lay the foundation for countries lacking large banks of thinkers and policy makers.
4. The MDGs have also increased the awareness of the public regarding their fundamental rights regarding health, education, and rights of women and children, which are important for the economic growth of the country.
5. The MDGs have highlighted the available opportunities, and ways to improve lives of individuals and the community in which they live.
6. The MDGs will be a success, so long as some progress is made towards the goals. It is the poorer countries that have the most progress to make towards the goals; thus any progress they make is inspiring.
7. It is important, therefore, that the success or failure of the Goals should not be judged simply by whether the goals are achieved by the year 2015, as long as progress has and is being made.
8. The target of 2015 gives a motivation. No target, no aim; no aim, no motivation, hence no progress.

In spite of the wide acceptance of MDGs and worldwide activity towards achieving the targets, there are critics.

THE CONS

1. The critics feel both that the MDGs are too narrow and, hence, the implementation is too narrow as well.
2. MDGs only focus only on economic, social and cultural rights, and not the corresponding civil and political rights.

3. Even within economic, social, and cultural rights, opponents further criticize the Goals because they do not include targets for expanding people's participation in government, increasing employment opportunities, reproductive health care rights, and institutional governance reforms.
4. Similarly, critics disapprove of the narrow indicators used to measure progress towards the Goals. These critics do not consider indicators such as school enrollment gaps to be a meaningful measurement of human development progress.
5. The underlying concern is that just because countries may lack a certain number of telephones or statistically have an equal number of boy and girl students enrolled in school, does not necessarily mean that the Millennium Development Goal that the indicators relate to is being met (or that a country is falling short).

In my view, MDGs #4 and #5, regarding school enrollment and the equality of educational opportunities for boys and girls, and access to telephones, is too important to ignore. First, harnessing the brains of future citizens is critical to nation-building; closing school enrollment and equality gaps should, therefore, be considered a priority. The number of telephones on its face value may not sound like a rather significant achievement; however, telephones have been a significant and noticeable contribution to growth of human development.

In response, supporters of the MDGs respond that the MDG indicators cannot be taken out of context, viewing the indicators not as ends in themselves, but rather as benchmarks of progress towards the broader goal to which they relate.

6. Other commentators criticize the very concept of having global goals and criticize the MDGs in particular for being too idealistic and setting the stage for disappointment. *Without aiming high you will remain where you are forever.*
7. Here, the concern is that countries that fail to meet the Goals by 2015, or that do not make sufficient progress towards that end, will be stigmatized as failures, resulting in further political separation between rich and poor countries. *Indeed, not so these countries would need more help, cajoling or other plans from global leadership.*
8. The critics are also concerned that, while the Goals may be attainable at the global level, it may be impractical to expect all regions and countries to reach the various indicators and targets. *This is but to be expected and normal; nothing wrong.*
9. Some countries have objected to the vast influence that donors have over how countries approach the implementation of the MDGs. Many communities feel that local officials have been undermined by the agendas of donors and UN agencies, instead of allowing communities to take their own approach to reaching the MDGs. *These are genuine concerns.*



The Barth Syndrome Foundation

P.O. Box 974, Perry, FL 32348

Tel: 850.223.1128

info@barthsyndrome.org

www.barthsyndrome.org

Symptoms: Cardiomyopathy, Neutropenia, Muscle Weakness, Exercise Intolerance, Growth Retardation

10. Many countries have expressed concern about the practice of relying on statistics to evaluate country and region progress. While statistics may be useful in measuring global progress overall, averages can be misleading since progress typically varies even within a single country. These critics note that statistical averages have a tendency to lead to unwarranted conclusions not based on real observations. *I agree, however, averages are only for comparison. Countries should make self-assessment and self-evaluations.*
11. The MDGs will only be successful in open, participatory political cultures. *This is very true, and underlies all the MDGs.*

It is important to recognize that the Goals must be supported by political will if they are to succeed. Both the people and governments, at both the national and local levels, must feel that the MDGs are their own goals, and not just those of the international community. People and local governments must work together in the decision-making process for the Goals to have a higher likelihood of success.

Despite the various pros and cons of the Millennium Development Goals, one thing is clear – the international community has taken them seriously, and it is still hopeful that the Goals will be met in the next five years.

It is clear that MDG #8 is fundamental to the success of implementing all other MDGs. The Minister from Uruguay emphasized the need for complying with MDG #8 by all member states as he spoke to a high-level plenary meeting of the UN General Assembly on the Millennium Development Goals (MDGs).

"Compliance with development goal number eight is essential for achieving the other millennium development goals, since commitment to development must be a collective commitment," of states of the globe. He said that though his country has been doing its part in working toward the MDGs, such cooperation between countries is very helpful in facilitating development progress."

"International trade, technology transfer, affordable access to medicines, an endur-

“Despite the various pros and cons of the Millennium Development Goals, one thing is clear – the international community has taken them seriously, and it is still hopeful that the Goals will be met in the next five years.”

ing solution to the problems of external debt and compliance with the commitments to ODA (official development assistance), just to mention a few of the goals established in this framework, are fundamental in the efforts carried out at all levels in order to achieve development," Lemes said.

The world's rich countries agreed to give 0.7% of their gross national income as official international development aid, annually. However, only five European countries, namely Norway, Sweden, Luxembourg, the Netherlands and Denmark, have carried out their pledges.

There is much more to be done, and ***“The Clock is Ticking!”***

NT



*Dharmapuri Vidyasagar, MD, FAAP, FCCM
University of Illinois at Chicago
Professor Emeritus Pediatrics
Division of Neonatology
Phone: +1.312.996.4185
Fax: +1.312.413.7901
dvsagarmd@yahoo.com*

NEONATOLOGY TODAY

© 2011 by Neonatology Today
ISSN: 1932-7129 (print); 1932-7137 (online).
Published monthly. All rights reserved.

Publishing Management

Tony Carlson, Founder & Senior Editor
Richard Koulbanis, Publisher & Editor-in-Chief
John W. Moore, MD, MPH, Medical Editor

Editorial Board: Dilip R. Bhatt, MD; Barry D. Chandler, MD; Anthony C. Chang, MD; K. K. Diwakar, MD; Willa H. Drummond, MD, MS (Informatics); Philippe S. Friedlich, MD; Lucky Jain, MD; Patrick McNamara, MD; David A. Munson, MD; Michael A. Posencheg, MD; DeWayne Pursley, MD, MPH; Joseph Schulman, MD, MS; Alan R. Spitzer, MD; Dharmapuri Vidyasagar, MD; Leonard E. Weisman, MD; Stephen Welty, MD; Robert White, MD; T.F. Yeh, MD

FREE Subscription - Qualified Professionals

Neonatology Today is available free to qualified medical professionals worldwide in neonatology and perinatology. International editions available in electronic PDF file only; North American edition available in print. Send an email to: SUBS@Neonate.biz. Include your name, title(s), organization, address, phone, fax and email.

Sponsorships and Recruitment Advertising

For information on sponsorships or recruitment advertising call Tony Carlson at 301.279.2005 or send an email to TCarlsonmd@gmail.com

824 Elmcroft Blvd.
Rockville, MD 20850 USA
Tel: +1.301.279.2005; Fax: +1.240.465.0692
www.NeonatologyToday.net

NEONATOLOGY TODAY CALL FOR CASES AND OTHER ORIGINAL ARTICLES

Do you have interesting research results, observations, human interest stories, reports of meetings, etc. to share?

Submit your manuscript to:
RichardK@Neonate.biz



Saving and improving lives of those with Hypertrophic Cardiomyopathy since 1996

328 Green Pond Road
PO Box 306
Hibernia, NJ 07842
Tel: 973-983-7429 Fax: 973-983-7870

www.4hcm.org



**ADVANCING
CRITICAL CARE**

www.ikaria.com

Customer Service 24/7/365:
+1-877-KNOW-INO (+1-877-566-9466)

Visit us at NEO booths 112 and 114

Advancing our commitment to innovation in the NICU

Two new products from
Mead Johnson Nutrition
to help meet the needs of your
smallest infants



Enfamil® Liquid Human Milk Fortifier



Enfamil® Premature High Protein 24 Cal

Part of a portfolio of premature formulas



NICU = neonatal intensive care unit



Expert nutrition at any stage.